Are Lymphokine Activated Killer Cells a Possible Form of Leukaemia Immunotherapy?

  • J. A. Tratkiewicz
  • J. Szer
  • R. L. Boyd
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 237)


The culture of freshly isolated lymphocytes for three to five days in vitro with a lymphokine preparation rich in interleukin 2 (IL-2), results in the generation of effector cells capable of lysing a variety of tumour cells1. This phenomenon has been described as lymphokine activated killing (LAK) and represents a lytic system distinct from that of natural killer (NK) cells2 and cytotoxic T lymphocytes3. Subsequent studies have revealed that LAK cells mainly arise from non-B, non-T lymphoid cell precursors and are capable of expanding for short times both in vivo and in vitro when stimulated by IL-24.


Natural Killer Peripheral Blood Mononuclear Cell Acute Leukaemia Cytosine Arabinoside Activate Killer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lotze M.T., Grimm EA., Mazumder A., Strausser J.L., Rosenberg S.A., Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T cell growth factor. Cancer Res. 41: 4420, (1981).PubMedGoogle Scholar
  2. 2.
    Grimm EA., Maxumder A., Zhang H.Z., Rosenberg S.A., Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interkeukin 2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155: 1823, (1982).PubMedCrossRefGoogle Scholar
  3. 3.
    Grimm EA., Ramsey K.M. Mazumder A., Wilson DJ., Djeu J.Y., Rosenberg S.A., Lymphokine activated killer cell phenomenon II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes and natural killer cells. J. Exp. Med. 157: 884, (1983).PubMedCrossRefGoogle Scholar
  4. 4.
    Ettinghausen S.E., Lipford E.H., Mule J.J., Rosenberg S.A., Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine activated killer cells. J. Immunol. 135: 3623, (1985).PubMedGoogle Scholar
  5. 5.
    Ettinghausen S.E., Rosenberg S.A., Immunotherapy of murine sarcomas using lymphokine activated killer cells: Optimization of the schedule and route of administration of recombinant interleukin 2. Cancer Res. 46: 2784, (1986).PubMedGoogle Scholar
  6. 6.
    Jacobs S.K., Wilson DJ., Kornblith P.L., Grimm EA., Interleukin 2 and autologous lymphokine activated killer cells in the treatment of malignant glioma. J. Neurosurg. 64: 743, (1986).PubMedCrossRefGoogle Scholar
  7. 7.
    Zarling J.M., Eskra L., Borden E.C., Horoszewicz J., Carter W.A., Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J. Immunol. 123: 63, (1979).PubMedGoogle Scholar
  8. 8.
    Yates J., Glidewell O., Wiernik P., Cooper M.R., Steinberg D., Dosik H., Levy R., Hoagland C., Henry P., Gottlieb A., Cornell C, Berenberg J., Hutchinson J.L., Raich P., Nissen N., Ellison R.R., Frelick R., James G.W., Falkson G., Silver R.T, Haurani F., Green M., Henderson E., Leone L., Holland J.F., Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60: 454, (1982).PubMedGoogle Scholar
  9. 9.
    Andersson C.C., Nilsson K., Gahmberg C.G., K562-a human erythroleukaemic cell Une. Int. J. Cancer 23: 143, (1979).PubMedCrossRefGoogle Scholar
  10. 10.
    Sundstron C, Nilsson K., Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int. J. Cancer 17: 565, (1976).CrossRefGoogle Scholar
  11. 11.
    Brunner K., Engers H., Cerottini J.C., The Cr release assay as used for the quantitative measurement of cell-mediated cytolysis in vitro, in: “In vitro methods in cell mediated and tumor immunity,” Bloom B, David J eds., Academic Press 1976, p 423.Google Scholar
  12. 12.
    Mazumder A., Rosenberg S.A., Successful immunotherapy of natural killer-resistant established pulmonary metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J. Exp. Med. 159: 495, (1984).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • J. A. Tratkiewicz
    • 1
  • J. Szer
    • 1
  • R. L. Boyd
    • 1
  1. 1.Alfred Hospital and Monash UniversityPrahranAustralia

Personalised recommendations